ABL Diagnostics signs LOI to buy Vela Diagnostics units in Singapore, US

• ABL Texcell Diagnostics signed a non-binding letter of intent to buy Vela Diagnostics’ operations in Singapore and the US.
• The deal targets 100% of Vela Operations Singapore and Vela Diagnostics USA from VDH Holding, parent of the Vela Group.
• Transaction would extend coverage beyond EMEA into Asia-Pacific and the US, building on an existing EMEA distribution partnership.
• Completion remains subject to due diligence and definitive documentation; no change in control is expected at ABL Texcell Diagnostics.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ABL Diagnostics SA published the original content used to generate this news brief via Business Wire (Ref. ID: 20260921418220) on September 21, 2026, and is solely responsible for the information contained therein.